Used in clinical research for the treatment of major depressive disorder and anxiety-related conditions. Acts as a selective and irreversible inhibitor of fatty acid amide hydrolase (FAAH), leading to increased levels of endocannabinoids such as anandamide in the brain. This mechanism modulates neurotransmission and neuroinflammation, offering potential therapeutic effects in mood and anxiety disorders without the psychoactive effects associated with direct cannabinoid receptor agonists. Has been investigated in phase I and II trials to evaluate safety, pharmacokinetics, and efficacy in humans.